Highlights Precigen, Inc.

Equities

PGEN

US74017N1054

Market Closed - Nasdaq Other stock markets 21:00:00 25/06/2024 BST			5-day change	1st Jan Change
1.67 ^USD	+3.73%		+6.37%	+24.63%

06-04	Transcript : Precigen, Inc. - Special Call
06-03	Stifel Adjusts Precigen's Price Target to $10 From $7, Keeps Buy Rating	MT

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Precigen Share Rise After Recurrent Respiratory Papillomatosis Study Shows 51% of Patients Surgery Free	06-03	MT
Precigen, Inc. Announces Groundbreaking Pivotal Study Data for PRGN-2012 in Patients with Recurrent Respiratory Papillomatosis in Which More Than Half of Patients Achieved Complete Response	06-03	CI
Precigen, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	05-14	CI
Earnings Flash (PGEN) PRECIGEN Reports Q1 Revenue $1.1M, vs. Street Est of $1.5M	05-14	MT
Precigen, Inc. to Present Late-Breaking Abstract for Pivotal Phase 2 Study Data for PRGN- 2012 AdenoVerse Immunotherapy	04-24	CI
North American Morning Briefing : Tech in Focus on -2-	03-25	DJ
Precigen, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	03-19	CI
Precigen, Inc. Receives Orphan Drug Designation for PRGN- 2012 for the Treatment of Recurrent Respiratory Papillomatosis from the European Commission	01-16	CI
Precigen Q3 Net Loss Widens, Revenue Falls	11-09	MT
Precigen, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-09	CI
Earnings Flash (PGEN) PRECIGEN Posts Q3 Revenue $1.4M	11-09	MT
Earnings Flash (PGEN) PRECIGEN Reports Q2 Revenue $1.8M, vs. Street Est of $2.2M	09/08/23	MT
Precigen, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	09/08/23	CI
Precigen, Inc Announces FDA Confirmation that the Ongoing Phase 1/2 Study of PRGN-2012 AdenoVerse Immunotherapy Will Serve as the Pivotal Study to Support Accelerated Approval	09/08/23	CI
Precigen Gets US FDA Grants Breakthrough Therapy Designation to PRGN-2012 for Recurrent Respiratory Papillomatosis Treatment	20/06/23	MT
Precigen Receives Breakthrough Therapy Designation for PRGN-2012 AdenoVerseâ„¢ Immunotherapy for the Treatment of Recurrent Respiratory Papillomatosis	20/06/23	CI
Precigen Unveils Positive Phase 1 Data From Advanced Stage Platinum Resistant Ovarian Cancer Patients	05/06/23	MT
Precigen Announces Positive Phase 1 Data for PRGN-3005 Autologous UltraCAR-T Cells Manufactured Overnight for Infusion Next Day to Advanced Stage Platinum Resistant Ovarian Cancer Patients	05/06/23	CI
Precigen Announces Positive Phase 1 Data for Off-the-Shelf PRGN-2009 AdenoVerse Immunotherapy Alone and in Combination with an Investigational Checkpoint Inhibitor in Patients with Recurrent/Metastatic HPV-associated Cancers	03/06/23	CI
Precigen, Inc. Receives FDA Clearance of IND to Initiate Phase 2 Study of PRGN-2009 Off-the Shelf AdenoVerse Immunotherapy in Combination with Pembrolizumab to Treat Patients with Recurrent or Metastatic Cervical Cancer	31/05/23	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Precigen, Inc.

Equities

PGEN

US74017N1054

Highlights

Filters